Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback

TACTILE SYSTEMS TECHNOLOGY INC

2024-Q3 EPS reported $0.30 revenue$207,399,000

Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.
Net income $5.2M ($0.21 diluted) vs $22.3M in Q3 2023; adjusted EBITDA $10.7M vs $7.7M.
Gross margin improved to 75.0% from 70.9%; operating expenses up 16%.
FY2024 revenue guidance narrowed to $292-295M (prior $293-298M; growth 6-8%).
Board authorized up to $30M share repurchase program through Oct 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.